Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase III study of HOB-294 in patients with overactive bladder
jRCT2080221273Phase 3
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of imidafenacin in overactive bladder (OAB), sponsored by Hisamitsu Pharmaceutical Co., Inc.
02
Drugs
imidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCT2080221273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221273.